BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 29223419)

  • 1. Posttransplant Lymphoproliferative Disorders in Epstein-Barr Virus Donor Positive/Recipient Negative Lung Transplant Recipients.
    Courtwright AM; Burkett P; Divo M; Keller S; Rosas IO; Trindade A; Mody GN; Singh SK; El-Chemaly S; Camp PC; Goldberg HJ; Mallidi HR
    Ann Thorac Surg; 2018 Feb; 105(2):441-447. PubMed ID: 29223419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary Epstein-Barr virus infection, seroconversion, and post-transplant lymphoproliferative disorder in seronegative renal allograft recipients: a prospective cohort study.
    Hosseini-Moghaddam SM; Alhomayeed B; Soliman N; Weir MA; House AA
    Transpl Infect Dis; 2016 Jun; 18(3):423-30. PubMed ID: 27016725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
    Nephrol Dial Transplant; 2012 Jul; 27(7):2971-9. PubMed ID: 22273720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-transplant lymphoproliferative disease in lung transplantation: A nested case-control study.
    Leyssens A; Dierickx D; Verbeken EK; Tousseyn T; Verleden SE; Vanaudenaerde BM; Dupont LJ; Yserbyt J; Verleden GM; Van Raemdonck DE; Vos R
    Clin Transplant; 2017 Jul; 31(7):. PubMed ID: 28383790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient.
    Aris RM; Maia DM; Neuringer IP; Gott K; Kiley S; Gertis K; Handy J
    Am J Respir Crit Care Med; 1996 Dec; 154(6 Pt 1):1712-7. PubMed ID: 8970360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epstein-Barr virus-associated post-transplant lymphoproliferative disorders in pediatric transplantation: A prospective multicenter study in the United States.
    Tajima T; Martinez OM; Bernstein D; Boyd SD; Gratzinger D; Lum G; Sasaki K; Tan B; Twist CJ; Weinberg K; Armstrong B; Desai DM; Mazariegos GV; Chin C; Fishbein TM; Tekin A; Venick RS; Krams SM; Esquivel CO
    Pediatr Transplant; 2024 Jun; 28(4):e14763. PubMed ID: 38682750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A low incidence of posttransplant lymphoproliferative disorder in 109 lung transplant recipients.
    Levine SM; Angel L; Anzueto A; Susanto I; Peters JI; Sako EY; Bryan CL
    Chest; 1999 Nov; 116(5):1273-7. PubMed ID: 10559086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased risk of PTLD in lung transplant recipients with cystic fibrosis.
    Lowery EM; Adams W; Grim SA; Clark NM; Edwards L; Layden JE
    J Cyst Fibros; 2017 Nov; 16(6):727-734. PubMed ID: 28456611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence of Epstein-Barr virus heterogeneous gene expression in adult lung transplant recipients with posttransplant lymphoproliferative disorder.
    Zaffiri L; Frankel C; Bush EJ; Neely ML; Pavlisko EN; Mokrova IL; Luftig MA; Palmer SM
    J Med Virol; 2021 Aug; 93(8):5040-5047. PubMed ID: 33704812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients.
    Smith JM; Corey L; Healey PJ; Davis CL; McDonald RA
    Transplantation; 2007 Jun; 83(11):1423-8. PubMed ID: 17565314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
    Gao XN; Lin J; Wang LJ; Li F; Li HH; Wang SH; Huang WR; Gao CJ; Yu L; Liu DH
    Ann Hematol; 2019 Sep; 98(9):2163-2177. PubMed ID: 31243569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epstein-Barr virus primary mismatching and HLA matching: key risk factors for post lung transplant lymphoproliferative disease.
    Wong JY; Tait B; Levvey B; Griffiths A; Esmore DS; Snell GI; Williams TJ; Kotsimbos TC
    Transplantation; 2004 Jul; 78(2):205-10. PubMed ID: 15280679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case Report: Non-negligible Epstein-Barr virus-associated posttransplant lymphoproliferative disorders in a lung transplant recipient.
    Hu J; Yu YW; Han DS; Li XJ; Zhang YQ; Cai HL; Xiao YH; Zheng X
    Front Immunol; 2023; 14():1244534. PubMed ID: 37781359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiopathic pulmonary fibrosis lung transplant recipients are at increased risk for EBV-associated posttransplant lymphoproliferative disorder and worse survival.
    Iasella CJ; Winters SA; Kois A; Cho J; Hannan SJ; Koshy R; Moore CA; Ensor CR; Lendermon EA; Morrell MR; Pilewski JM; Sanchez PG; Kass DJ; Alder JK; Nouraie SM; McDyer JF
    Am J Transplant; 2020 May; 20(5):1439-1446. PubMed ID: 31874120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence, Risk Factors, Clinical Management, and Outcomes of Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients.
    Liu M; Husain S; Famure O; Li Y; Kim SJ
    Prog Transplant; 2019 Jun; 29(2):185-193. PubMed ID: 30845885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Posttransplant lymphoproliferative disorders in lung transplant recipients: clinical experience at a single center.
    Angel LF; Cai TH; Sako EY; Levine SM
    Ann Transplant; 2000; 5(3):26-30. PubMed ID: 11147026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiology of posttransplantation lymphoproliferative disorder in adult renal transplant recipients.
    Morton M; Coupes B; Roberts SA; Klapper PE; Byers RJ; Vallely PJ; Ryan K; Picton ML
    Transplantation; 2013 Feb; 95(3):470-8. PubMed ID: 23222821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single-center Experience.
    Peters AC; Akinwumi MS; Cervera C; Mabilangan C; Ghosh S; Lai R; Iafolla M; Doucette K; Preiksaitis JK
    Transplantation; 2018 Sep; 102(9):1553-1562. PubMed ID: 29485513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-transplantation lymphoproliferative disease: Epstein-Barr virus DNA levels, HLA-A3, and survival.
    Wheless SA; Gulley ML; Raab-Traub N; McNeillie P; Neuringer IP; Ford HJ; Aris RM
    Am J Respir Crit Care Med; 2008 Nov; 178(10):1060-5. PubMed ID: 18755927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of Epstein-Barr virus status and post-transplant lymphoproliferative disease in pediatric thoracic transplantation.
    Harwood JS; Gould FK; McMaster A; Hamilton JR; Corris PA; Hasan A; Gennery AR; Dark JH
    Pediatr Transplant; 1999 May; 3(2):100-3. PubMed ID: 10389130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.